Speaking at the Irish Medical Organisation’s annual meeting in Killarney, Prof Barry pointed to what could be the “next big ...

Where are you on your gen AI journey? This guide by CNET's experts will point you in the right direction. Jon Skillings is an ...

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of ...

Eligible participants were aged 50 and over, had a diagnosis of tT2D, and no prior history of dementia or use of ...

Small molecules with big potential The two drugs used in this study are already approved to treat rare cancers. Tazemetostat, known under the brand name Tazverik, was approved by the U.S. FDA in ...

2025 — Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year, diabetes experts ... Mar. 27, 2025 — A research team has ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Diabetes strikes 42 million in Canada and the US, can cannabis make a difference? The loss of Gossip Girl start Michelle Tractenberg has put diabetes in the national attention, Tractenberg ...

The move comes less than a week after Novo’s largest rival, American company Eli Lilly, announced successful clinical trial results for its new oral diabetes medication, which also had ...

Trusted, comprehensive information and resources for your diabetes journey.

(Reuters) -A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal ...

According to court documents, Eli Lilly accuses Empower Pharmacy of allegedly selling potentially dangerous versions of its drugs Mounjaro and Zepbound — two injectable medications containing ...